Jl. Abbruzzese et al., ANALYSIS OF A DIAGNOSTIC STRATEGY FOR PATIENTS WITH SUSPECTED TUMORS OF UNKNOWN ORIGIN, Journal of clinical oncology, 13(8), 1995, pp. 2094-2103
Purpose: Diagnostic strategies designed to identify the underlying pri
mary malignancies in patients with unknown primary tumors (UPTs) have
relied on retrospective analyses. We analyzed 879 consecutive patients
referred with suspected UPTs to determine the yield and cost of a lim
ited diagnostic evaluation, assess the contribution of specific studie
s to diagnosis, and analyse the survival patterns of patients in whom
the primary tumor was diagnosed. Patients and Methods: Data from patie
nts with a suspected UPT were entered into a computerized data base, a
nd the patients underwent a predefined limited diagnostic evaluation.
Primary malignancies were diagnosed by pathologic review alone or by p
athologic criteria plus a physical or radiographic finding. Survival w
as measured from diagnosis, estimated using the Kaplan-Meier method, a
nd compared using the Cox-Mantel log-rank test. Results: A primary tum
or was found in 179 of 879 patients (20%). The survival duration of pa
tients in whom the primary tumor was diagnosed was superior to that of
patients in whom the primary tumor remained unknown. Specific patient
subsets contributed most to the improved survival duration of the gro
up in which the primary tumor was found, including lymphoma patients d
iagnosed solely by pathologic criteria and female patients with primar
y breast or ovarian cancer. The cost of diagnosis was mostly due to th
e extensive use of computed tomography. Except for ovarian cancer, com
puted tomography rarely identified treatable primary tumors. Conclusio
n: The limited diagnostic evaluation used in this study identified pat
ients with treatable malignancies and increased the survival duration
of a population of suspected UPT patients. Primary malignancies with t
he best survival can be diagnosed through careful pathologic review an
d focused evaluations for breast and ovarian cancer in women. (C) 1995
by American Society of Clinical Oncology.